Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 12/2006

01-12-2006 | Original Article

Macrophage inflammatory protein (MIP)1α and MIP1β differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy

Authors: Anamika Nath, Sreya Chattopadhya, Utpala Chattopadhyay, Nawal K. Sharma

Published in: Cancer Immunology, Immunotherapy | Issue 12/2006

Login to get access

Abstract

The C–C chemokines, macrophage inflammatory protein (MIP)1α and MIP1β are potent chemoattractants for the monocytes, which form an important component of the stroma of tumor tissue and may regulate tumor growth and associated inflammation. We examined the role of MIP1α and MIP1β in inducing the release of inflammatory cytokines and the generation of tumoricidal monocytes from the peripheral blood monocytes (PBM) of healthy women and patients with carcinoma of breast (CaBr). Interleukin-1 (IL-1) and tumor necrosis factor (TNF) α release by the PBM was markedly stimulated by MIP1α in CaBr patients, but only marginally so in healthy women. In contrast, MIP1β stimulated the release of these cytokines by the PBM of healthy women, but failed to do so in CaBr patients. MIP1α, but not MIP1β, synergized with LPS in inducing the release of IL-1 from the PBM of both healthy women and CaBr patients. Both MIP1α and MIP1β augmented respiratory bursts in PBM and generated tumoricidal PBM that killed T24 cells, MIP1α being more effective in CaBr patients and MIP1β in healthy women. IFN-γ co-stimulated and IL-4 suppressed MIP1α and β-induced cytotoxicity in PBM. The synergy of IFN-γ was more marked with MIP1α than with MIP1β. The differential effects of MIP1α and MIP1β on the PBM of healthy women and CaBr patients co-related with the levels of expression of CCR1 and CCR5 in these monocytes. The expression of CCR5 was higher than that of CCR1 in the PBM of healthy women and the PBM of the CaBr patients showed overexpression of CCR1 and downregulation of CCR5.
Literature
1.
Asano T, An T, Jia SF, Kleinerman ES (1996) Altered monocyte chemotactic and activating factor gene expression in human glioblastoma cell lines increased their susceptibility to cytotoxicity. J Leukoc Biol 59:916PubMed
2.
Austrup F, Vestweber D, Borges E, Lohning M, Brauer R, Herz U, et al. (1997) P and E-selectin mediated recruitment of T helper 1 but not T helper 2 cells into inflamed tissues. Nature 385:81CrossRefPubMed
3.
Baggiolini M, Dewald B, Moser B (1994) Interleukin-8 and related chemo tactic cytokines-CXC and CC chemokines. Adv Immunol 55:97PubMed
4.
Beckner SK (1997) G-protein activation by chemokines. Methods Enzymol 288:311
5.
Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibandi D, et al. (1999) Tumor associated transforming growth factor beta and interleukin –10 contribute to a systemic TH-2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155:537PubMed
6.
Chakraborty A, Chakrabarty NG, Chattopadhyay U (1996) Prolactin responses of NK cells but not of LAK cells is deficient in oral cancer patients. Int J Cancer 66:65CrossRefPubMed
7.
Chattopadhyay U, Biswas R (2002) Prolactin regulates macrophage and NK cell mediated inflammation and cytotoxic response against tumor. In: Rapaport R, Matera L (eds) Growth and lactogenic hormone, vol 2. Neuroimmune biology Elsevier science. Amsterdam, p 227
8.
Chensue SW, Ruth JH, Warmington K, Lincoln P, Kunkel SL (1995) In vivo regulation of macrophage IL-12 production during type 1 and type 2 cytokine mediated granuloma formation. J Immunol 155:3546PubMed
9.
Cianciolo GJ, Hunter J, Silva J, Haskill JS, Snyderman R (1981) Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to P15 (E) structural protein of retroviruses. J Clin Invest 68:831PubMedCrossRef
10.
Cohn ZA (1978) The activation of mononuclear phagocytes: fact, fancy and future. J Immunol 121:813PubMed
11.
Conlon K, Llyod AR, Chattopadhyay U, Lucas N, Kunkel S, Schall T, et al. (1995) CD8+ and CD45RA+ human peripheral blood lymphocytes are potent source of macrophage inflammatory protein 1 alpha, IL-8 and RANTES. Eur J Immunol 25:751PubMedCrossRef
12.
Cox GW, Chattopadhyay U, Oppenheim JJ, Varesio L (1991) IL-4 inhibits the co-stimulatory activity of IL-2 or picolinic acid but not of lypopolysaccharide on IFN-γ treated macrophages. J Immunol 147:3809PubMed
13.
Decker T, Lohmann-Matthes MJ (1988) A quick and simple method for quantification of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 15:61CrossRef
14.
Della-Rocca GJ, WanBiesen T, Daaka Y, Luttrell DK, Luttrell LM, Lefkowitz RJ (1997) Ras-dependent mitogen activated protein kinase activation by G protein coupled receptors. Convergence of Gi and Gq-mediated pathways on calcium/calmodulin, Pyk2 and Src kinase. J Biol Chem 272:19125CrossRefPubMed
15.
Dias S, Thomas H, Blackwell F (1998) Multiple molecular and cellular changes associated with tumor stasis and repression during IL-12 therapy of a murine breast cancer model. Int J Cancer 75:151CrossRefPubMed
16.
Fahey TJ, Tracey KJ, Tekamp-Olson P, Cousens LS, Jones WG, Shires GT, et al. (1992) Macrophage inflammatory protein 1 modulates macrophage function. J Immunol 148:2764PubMed
17.
Flick DA, Gifford GE (1984) Comparision of invitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 68:167CrossRefPubMed
18.
Ganju RK, Dutt P, Wu L, Newman W, Avraham H, Avraham S, et al. (1998) Beta chemokine receptor CCR5 signals via the novel tyrosine kinase RAFTK. Blood 91:791PubMed
19.
Han J, Lee JD, Bibbs L, Ulevitch RL (1994) A MAP kinase activation by endotoxin and hyperosmomolarity in mammalian cells. Science 265:808–811PubMedCrossRef
20.
Huang S, Singh RK, Xie K, Gutman M, Berry KK, Bucana CD, et al. (1994) Expression of JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother 39:231CrossRefPubMed
21.
Jablonska E, Kiluk M, Piotrowski L, Grabowska Z, Markiewicz W, Jablonski J (1998) Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients. Eur Cytokine Netw 2:155
22.
Jiang Y, Beller DI, Frendl G, Graves DT (1992) Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 148:2423PubMed
23.
Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739CrossRefPubMed
24.
Loeffler CM, Smyth MJ, Longo DL, Kopp WC, Harvey LK, Tribble HR, et al. (1992) Immunoregulation in Cancer bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol 149:949PubMed
25.
Mantovani A, Bottazzi B, Collotta F, Sozzani S, Ruco L (1992) The origin and function of tumor associated macrophages. Immunol Today 13:265CrossRefPubMed
26.
Mantovani A, Vecchi A, Sozzani S, Sica A, Allavena P (1999) Tumors as a paradigm for the invivo role of chemokines in leukocytes recruitment. In: Rollins BJ (eds) Chemokines and cancer. Humana press, Totowa, NJ, p 35
27.
Miller MD, Krangel MS (1992) Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit Rev Immunol 12:17PubMed
28.
Mizel SB, Oppemheim JJ, Rosenstreich DL (1978) Characterization of lymphocyte activating factor (LAF) produced by macrophage cell line P388D1. I. Enhancement of LAF production by activated T lymphocytes. J Immunol 120:1497PubMed
29.
Mossman T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 65:55CrossRefPubMed
30.
Nishioka Y, Sone S, Orino Nii A, Ogura T (1991) Down regulation by interleukin-4 of activation of human alveolar macrophages to the tumoricidal state. Cancer Res 51:5526PubMed
31.
Opdenakker G, Van Damme J (1992) Cytokines and proteases in invasive process: molecular similarities between inflammation and cancer. Cytokine 4:251CrossRefPubMed
32.
Oppenheim JJ, Zachariae OC, Mukaida N, Matsushima K (1991) Properties of the novel proinflammatory supergene “Intercrine” cytokine family. Annu Rev Immunol 9:617PubMed
33.
Pike E, Mizel D (1981) Rapid microassay for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic immunoassay reader. J Immunol Methods 46:211CrossRefPubMed
34.
Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM (1986) An endothelial cell surface factor(s) induced in vitro by LPS, IL-1 and TNF-alpha increases neutrophil adherence by a CDW18-dependent mechanism. J Immunol 136:4548PubMed
35.
Sallusto F, Lanzavecchia A, Mackay CR (1998) Chemokines and chemokine receptors in T-cell priming and Th-1/Th-2 mediated responses. Immunol Today 19:568–574CrossRefPubMed
36.
Schrum S, Probst P, Fleischer B, Zipfel PF (1996) Synthesis of the C–C chemokines MIP1α, MIP1β and RANTES are associated with a type 1 immune response. J Immunol 157:3598PubMed
37.
Selvan RS, Kapadia HB, Platt JL (1998) Complement induced expression of chemokine genes in endothelium: regulation by IL-1 dependent mechanisms. J Immunol 161:4388PubMed
38.
Singh RK, Berry K, Matsushima K, Yasumoto K, Fidler IJ (1993) Synergism between human monocyte chemotactic and activating factor and bacterial products for activation of tumoricidal property of murine macrophages. J Immunol 151:2786PubMed
39.
Siveke JT, Hamann A (1998) Cutting edge: T helper 1 and T helper 2 cells responds differentially to chemokines. J Immunol 160:550PubMed
40.
Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ (1993) Preferential migration of activated CD4+ and CD8+ T cells in response to MIP1α and MIP1β?. Science 260:355PubMedCrossRef
41.
Taub DD (1999) Natural killer-cell-chemokine interactions. In: Rollins BJ (eds) Chemokines and Cancer. Humana press, Totowa, NJ, p 35
42.
Wang JM, Chertov O, Proost P, Li JJ, Menten P, Xu L, et al. (1998) Purification and identification of chemokines potentially involved in kidney-specific metastasis by a murine lymphoma variant: induction of migration and NF kβ activation. Int J Cancer 75:900CrossRefPubMed
43.
Wang JM, Deng X, Gong W, Su S (1998) Chemokines and their role in tumor growth and metastasis. J Immunol Methods 220:1CrossRefPubMed
44.
Wang JM, Shen W, Chertov O, Van Damme J, Oppenheim J (1999) Chemokine modulation of tumor cell physiology. In: Rollins BJ (eds) Chemokines and Cancer, Humana Press, Totowa, NJ, p 129
45.
Wiltrout RH, Varesio L (1990) Activation of macrophage for cytotoxic and suppressor effector functions. In: Oppenhein JJ, Shevarch EM (eds) Immunophysiology. The role of cells and cytokines in immunity and inflammation. Oxford University press, NY, pp365
46.
Zachariae CO, Anderson AO, Thompson HL, Apella E, Mantovani A, Oppenheim JJ, et al. (1990) Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med 171:2177CrossRefPubMed
47.
Zella D, Barabitskaja O, Burns JM, Romerio F, Dunn DE, Revello MG, et al. (1998) Interferon γ increases expression of chemokine receptors CCR1, CCR3 and CCR5, but not CXCR4 in monocytoid U937 cells. Blood 91:4444PubMed
Metadata
Title
Macrophage inflammatory protein (MIP)1α and MIP1β differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy
Authors
Anamika Nath
Sreya Chattopadhya
Utpala Chattopadhyay
Nawal K. Sharma
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0149-3

Other articles of this Issue 12/2006

Cancer Immunology, Immunotherapy 12/2006 Go to the issue

Original Article

CD40 ligation restores cytolytic T lymphocyte response and eliminates fibrosarcoma in the peritoneum of mice lacking CD4+ T cells

Original Article

Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28

Original Article

Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface

Original Article

Increased liver temperature efficiently augments human cellular immune response: T-cell activation and possible monocyte translocation

Original Article

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

Original Article

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits